加拿大老年人潜在不合适药物的成本:一个比较的横截面研究
Jean-François Huon1,2,3, Chiranjeev Sanyal4, Camille L Gagnon1
1Canadian Medication Appropriateness and Deprescribing Network, Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.
加拿大在潜在不合适药物 (PIMs) 上的支出在2021年下降了33.6%,至10亿美元. 然而,抗精神病药物等某些有害PIM的成本增加,需要针对老年人进行有针对性的干预.
科学领域:
- 老年人药理学 老年人药理学
- 卫生经济学 卫生经济学
- 公共卫生政策 公共卫生政策
背景情况:
- 潜在不合适的药物 (PIMs) 带来风险,特别是对老年人来说,其直接的医疗保健成本未得到充分记录.
- 了解PIMs的经济负担对于医疗保健资源分配和患者安全倡议至关重要.
研究的目的:
- 分析65岁及以上加拿大人与PIM相关的直接成本.
- 将2021年的PIM支出与2013年的数据进行比较,以确定趋势.
主要方法:
- 一项横截面研究,利用来自2013年和2021年国家处方药使用信息系统的处方索赔数据.
- 计算了通货膨胀调整后的年度总支出,每次风险平均季度成本,以及加拿大美元 (CAD$) 中的PIM季度平均风险.
- 来自美国老年病学协会的适应标准来识别PIMs.
主要成果:
- 对PIM的年度总支出从2013年的15亿美元下降了33.6%,到2021年的10亿美元.
- 尽管总体减少了,但对 gabapentinoids,质子抑制剂和抗精神病药物的支出增加了.
- 每位暴露者的季度成本从95美元降至57美元,整体PIM暴露率下降了16.4%.
结论:
- 虽然加拿大的PIM总体支出有所下降,但总成本仍然很大.
- 增加了高风险PIM的处方,包括抗精神病药和 gabapentinoids,强调了有针对性的干预措施的必要性.
- 需要进一步的研究和可扩展的干预措施,以减轻与老年人群中PIM相关的风险和成本.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
04:13Using a Real-Time Locating System to Measure Walking Activity Associated with Wandering Behaviors Among Institutionalized Older Adults
Published on: February 8, 2019
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Factors Affecting Drug Response: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
